Objective: The aim of this study was to evaluate the duration of the effect of an intravitreal
injection of approximately 20 mg of triamcinolone acetonide (TA) on visual acuity and
intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD)
with subfoveal choroidal neovascularization.
Participants: The prospective, clinical, interventional, case series study included 69 patients
(71 eyes) with exudative AMD who showed an increase in visual acuity by at least 2 Snellen
lines after an intravitreal injection of approximately 20 mg TA. Mean follow-up was 11.5 ±
7.4 months (3.3–35.7 months). The main outcome measure was visual acuity.
Results: Within the first week after the injection, visual acuity and IOP started to increase
significantly (P < 0.001) by reaching a plateau-like maximum at 1–6 months after the injection.
Visual acuity and IOP returned to baseline values 7–9 months after the injection. Increase
of IOP was statistically (P = 0.72) independent of the change in visual acuity.
Conclusions: In patients with exudative AMD, who have shown an increase of at least 2
Snellen lines in visual acuity, the effect of intravitreal TA (dosage approximately 20 mg) lasts
7–9 months with respect to an increase in visual acuity and IOP.
